SABS
SAB Biotherapeutics Inc
NASDAQ: SABS · HEALTHCARE · BIOTECHNOLOGY
$3.74
+7.47% today
Updated 2026-04-30
Market cap
$248.07M
P/E ratio
—
P/S ratio
2.96x
EPS (TTM)
$-0.79
Dividend yield
—
52W range
$2 – $5
Volume
0.6M
SAB Biotherapeutics Inc (SABS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-9.21M | $10.00M | $1.99M | $-23.46M | $-25.12M | $-34.29M | $-44.78M |
| Capital expenditures | $608748.00 | $12.73M | $10.94M | $2.17M | $197154.00 | $337262.00 | $933151.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $371388.00 | $1.30M | $2.31M | $2.67M | $2.42M | $2.94M | $5.21M |
| Free cash flow | $-9.82M | $-2.73M | $-8.96M | $-25.63M | $-25.32M | $-34.63M | $-45.71M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $26.93M | $-24.50M | — | — | — |